Roadmap and strategy for overcoming infusion reactions to nanomedicines

Janos Szebeni, Dmitri Simberg, África González-Fernández, Yechezkel Barenholz, Marina A. Dobrovolskaia*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

141 Scopus citations

Abstract

Infusion reactions (IRs) are complex, immune-mediated side effects that mainly occur within minutes to hours of receiving a therapeutic dose of intravenously administered pharmaceutical products. These products are diverse and include both traditional pharmaceuticals (for example biological agents and small molecules) and new ones (for example nanotechnology-based products). Although IRs are not unique to nanomedicines, they represent a hurdle for the translation of nanotechnology-based drug products. This Perspective offers a big picture of the pharmaceutical field and examines current understanding of mechanisms responsible for IRs to nanomedicines. We outline outstanding questions, review currently available experimental evidence to provide some answers and highlight the gaps. We review advantages and limitations of the in vitro tests and animal models used for studying IRs to nanomedicines. Finally, we propose a roadmap to improve current understanding, and we recommend a strategy for overcoming the problem.

Original languageEnglish
Pages (from-to)1100-1108
Number of pages9
JournalNature Nanotechnology
Volume13
Issue number12
DOIs
StatePublished - 1 Dec 2018

Bibliographical note

Publisher Copyright:
© 2018, This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply.

Fingerprint

Dive into the research topics of 'Roadmap and strategy for overcoming infusion reactions to nanomedicines'. Together they form a unique fingerprint.

Cite this